The Memory Inflation Response Against Spread-Defective CMV Requires Priming-Independent CD4+ T Cell Help | JoVE Visualize

Area of Science:

Immunology
Virology
T cell biology

Background:

Memory inflation (MI) is a unique CD8+ T cell response to chronic cytomegalovirus (CMV) infection.
These cells are effector-differentiated and non-contracting, making them a target for vaccination strategies using spread-defective CMV-vectors.
The precise role of CD4+ T cell help in CD8+ T cell MI remains incompletely understood.

Purpose of the Study:

To investigate the mechanistic aspects of CD8+ T cell MI responses, specifically their dependence on CD4+ T cell help.
To determine if CD4+ T cell help is required during initial priming or can be provided later to sustain MI.
To elucidate the role of CD4+ T cells in maintaining effector populations during chronic antigen exposure.

Main Methods:

Utilized a Rag KO transfer model to assess the impact of CD4+ T cells on CD8+ T cell MI.
Compared MI responses to both spread-defective and spread-competent CMV infections.
Administered late CD4+ T cell depletion in wild-type mice to evaluate sustained MI.
Performed gene set enrichment analysis to identify potential mediators of CD4+ T cell support.

Main Results:

CD4+ T cells enhance CD8+ T cell effector differentiation in MI when present during priming or introduced later, indicating continuous support.
This CD4+ T cell requirement is specific to spread-defective CMV; spread-competent CMV induces MI independently of CD4+ T cells.
Late CD4+ T cell depletion in wild-type mice attenuated established MI responses.
Gene set enrichment analysis suggests IFNγ, TNF, and IL-1 signaling pathways mediate CD4+ T cell support.

Conclusions:

CD4+ T cells provide essential, continuous help for maintaining CD8+ T cell effector populations in memory inflation during chronic antigen exposure.
The requirement for CD4+ T cell help is dependent on the viral spread competence, being critical for spread-defective CMV.
These findings are significant for developing spread-defective CMV-based vaccines and T cell therapies aiming for persistent, expanded effector populations.